Synergism between GM-CSF and IFNγ: Enhanced immunotherapy in mice with glioma

International Journal of Cancer

Volumn 120, Issue 1, 2007, Pages 75-80

  Smith, Karin K ^a,c   Janelidze, Shorena ^a   Visse, Edward ^a   Badn, Wiaam ^a   Salford, Leif ^b   Siesjö, Peter ^a,b   Darabi, Anna ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c BMC 112   (Sweden)

Author keywords

Autologous tumor cell; Glioma; GM CSF; IFN ; Therapeutic immunization

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE THERAPY; GENES, MHC CLASS I; GENES, MHC CLASS II; GENETIC VECTORS; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERFERON-GAMMA, RECOMBINANT; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; SURVIVAL RATE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33845422478     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22286     Document Type: Article

References (33)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
2. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
3. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-54.
4. Prell RA, Li B, Lin JM, VanRoey M, Jooss K. Administration of IFN-α enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 2005;65:2449-56.
5. Chen JC, Chen Y, Wu JM, Su YH, Tai KF, Tseng SH. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. Cancer Immunol Immunother 2006;55:873-83.
6. Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, Jolly D, Seigler HF. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or γ interferon. Cancer Gene Ther 1997;4:33-41.
7. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
8. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH, Vremec D, Robb L, Shortman K, McKenna HJ, Maliszewski CR, Maraskovsky E. Polyethylene glycol-moditied GM-CSF expands CD11b(high)CD11c (high) but notCD11b(low) CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000;165:49-58.
9. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophaae-colony-stimulating factor and interleukin-4. Blood 2002;99:2869-79.
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:1 1-22.
11. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakfield XO, Yu JS. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997;4:345-52.
12. Jean WC, Spellman SR, Wallenfriedman MA, Flores CT, Kurtz BP, Hall WA, Low WC. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J Neurooncol 2004;66:39-49.
13. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clifi S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte- macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
14. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-6.
15. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, Dasko D, Kim JA, Plautz GE, Leff BE, Smith V, Sandstrom-Wakeling K, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000;126:1225-31.
16. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
17. Akbasak A, Oldfield EH, Saris SC. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg 1991;75:922-9.
18. Visse E, Siesjo P, Widegren B, Sjogren HO. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther 1999;6:37-44.
19. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003;98:71-108.
20. Lumniczky K, Desaknai S, Mangel L, Szende B, Hamada H, Hidvegi E.I. Safrany G. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002;9:44-52.
21. Visse E, Johansson AC, Widegren B, Sjogren HO, Siesjo P. Immunohistochemical analysis of glioma-infiltraling leucocytes after peripheral therapeutic immunization with interferon-γ-transfected glioma cells. Cancer Immunol Immunother 2000;49:142-51.
22. Siesjo P, Visse E, Lindvall M, Salford L, Sjogren HO. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother 1993;37:67-74.
23. Nishisaka N, Maini A, Kinoshita Y, Yasumoto R, Kishimoto T, Jones RF, Morse P, Hillman GG, Wang CY, Haas GP. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J Immunother 1999;22: 308-14.
24. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G. Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J Exp Med 2003;197:1213-19.
25. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43.
26. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
27. Schiltz PM, Gomez GG, Read SB, Kulprathipanja NV, Kruse CA, Effects of IFN-γ and interleukin-1β on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. J Interferon Cytokine Res 2002;22:1209-16.
28. Paul DB, Read SB, Kulprathipanja NV, Gomez GG, Kleinschmidt-DeMasters BK, Schiltz PM, Kruse CA. γ interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes. J Neurooncol 2003;64:89-99.
29. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranotf G. Differences in dendritic cells stimulated in vivo by tumors engineered 10 secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-46.
30. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164:4507-12.
31. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
32. Baj-Krzyworzeka M, Baran J, Szatanek R, Stankiewicz D, Siedlar M, Zembala M. Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (PPD), and antiIL-10 antibody. Cancer Immun 2004;4:8.
33. Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Wieckiewicz J, Zembala M. Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 2003;74:1094-101.